Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: A GLOT-GFPC study

Annals of Oncology

Volumn 17, Issue 9, 2006, Pages 1412-1417

  Cortot, A B ^a   Geriniere L ^a   Robinet, G ^b   Breton, J L ^c   Corre, R ^d   Falchero, L ^c   Berard, H ^e   Gimenez, C ^f   Chavaillon, J M ^g   Perol, M ^h   Bombaron, P ⁱ   Mercier, C ^a   Souquet, Pierre Jean ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b CHU MORVAN   (France)

^c CENTRE HOSPITALIER   (France)

^d PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^e Military Teaching Hospital Sainte Anne   (France)

^f HÔPITAL SAINTE MARGUERITE   (France)

^g Centre Hospitalier de la Fontonne   (France)

^h CROIX ROUSSE HOSPITAL   (France)

ⁱ CENTRE HOSPITALIER DE MULHOUSE   (France)

Author keywords

Brain metastases; Cisplatin; NSCLC; Temozolomide

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; CORTICOSTEROID; MANNITOL; TEMOZOLOMIDE;

ADRENAL METASTASIS; ADULT; AGED; ANEMIA; APLASIA; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; BRAIN METASTASIS; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG TOLERABILITY; EDEMA; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYDRATION; LIVER METASTASIS; LUNG EMBOLISM; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SEPTICEMIA; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DACARBAZINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 33748744259     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl146     Document Type: Article

References (25)

1. Patchell RA, Tibbs PA, Walsh JW et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 332: 494-500.
2. Cola LR. The role of radiation therapy in the treatment of brain metastases. Int J Radiat Oncol Biol Phys 1992; 1: 229-238.
3. Stewart DJ, Leavens M, Maor M et al. Human central nervous system distributionof cis-diaminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 1982; 42: 2474-2479.
4. Raymond E, Izbicka E, Soda H et al. Activity of temozolomide against human tumor colony-forming units. Clin Cancer Res 1997; 3: 1769-1774.
5. Yung WK, Prados MD, Yaya-Tur R et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999; 17: 2763-2771.
6. Middleton MR, Grob JJ, Aaronson N et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-166.
7. Ostermann S, Csajka C, Buclin T et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004; 10: 3728-3736.
8. Baker SD, Wirth M, Statkevich P et al. Absorption, metabolism and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 1999; 5: 309-317.
9. Abrey LE, Olson JD, Raizer JJ et al. A phase II trial of TMZ for patients with recurrent or progressive brain metastases. J Neur Oncol 2001; 53: 259-265.
10. Christodoulou C, Bafaloukos D, Kosmidis P et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 2001; 12: 249-254.
11. Dziadziuszko R, Ardizzoni A, Postmus PE et al. Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases: A phase II study of the EORTC Lung Cancer Group (08965). Eur J Cancer 2003; 39: 1271-1276.
12. Giorgio CG, Giuffrida D, Pappalardo A et al. Oral temozolomide in heavily pre-treated brain metastases from non-small-cell lung cancer: phase II study. Lung Cancer 2005; 50: 247-254.
13. Wang LG, Setlow RB. Inactivation of 06-alkylguanine-DNA alkyltransferase in HeLa cells by cisplatin. Carcinogenesis 1989; 10: 1681-1684.
14. D'Atri S, Graziani G, Lacal PM et al. Attenuation of 06-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells. J Pharmacol Exp Ther 2000; 294: 664-671.
15. Piccioni D, D'Atri S, Papa G et al. Cisplatin increases sensitivity of human leukemic blasts to triazene compounds. J Chemother 1995; 7: 224-229.
16. Britten CD, Rowinsky EK, Baker SD et al. A phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res 1999; 5: 1629-1637.
17. National Cancer Institute: Reporting guidelines, Common Toxicity Criteria V2.E (CTC). http://ctep.cancer.gov:reporting:CTC-3.html.
18. Robinet G, Thomas P, Breton L et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1. Ann Oncol 2001; 12: 59-67.
19. Antonadou D, Paraskevaidis M, Sarris G et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002; 20: 3644-3650.
20. Ebert BL, Niemerko E, Shaffer K et al. Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Oncologist 2003; 8: 69-75.
21. Daponte A, Ascierto PA, Gravina A et al. TMZ and cisplatin in avdanced malignant melanoma. Anticancer Res 2005; 25: 1441-1447.
22. Tas F, Argon A, Camlica H, Topuz E. Temozolomide in combination with cisplatin in patients with metastatic melanoma: A phase II trial. Melanoma Res 2005; 15: 543-548.
23. Christodoulou C, Bafaloukos D, Linardou H et al. Hellenic Cooperative Oncology Group. Temozolomide combined with cisplatin in patients with brain metastases from solid tumors: A Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neurooncol 2005; 71: 61-65.
24. Franciosi V, Cocconi G, Michiara M et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, non-small-cell lung carcinoma, or malignant melanoma: A prospective study. Cancer 1999; 85: 1599-1605.
25. Minotti V, Crino L, Meacci ML et al. Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer. Lung Cancer 1998; 20: 93-98.